Abstract
Breast cancer remains a significant challenge in the field of oncology, particularly the aggressive triple-negative breast cancer (TNBC) subtype, accounting for 15-20% of cases. TNBC lacks estrogen, progesterone, and HER2 receptors, making it difficult to target with conventional therapies. In light of this, there is an urgent need to explore novel treatment approaches that can effectively address the unique characteristics of TNBC
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
